Author:
Traynor Anne M.,Lee Ju-Whei,Bayer Gerald K.,Tate John M.,Thomas Sachdev P.,Mazurczak Miroslaw,Graham David L.,Kolesar Jill M.,Schiller Joan H.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference28 articles.
1. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98 doi: 10.1056/NEJMoa011954
2. Crino L, Mosconi AM, Scagliotti G et al (1999) Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 17:2081–2085
3. Brodowicz T, Krzakowski M, Zwitter M et al (2006) Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 52:155–163 doi: 10.1016/j.lungcan.2006.01.006
4. Murren J, Modiano M, Clairmont C et al (2003) Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res 9:4092–4100
5. Yu Y, Wong J, Lovejoy DB et al (2006) Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin Cancer Res 12:6876–6883 doi: 10.1158/1078-0432.CCR-06-1954
Cited by
100 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献